LXRX - Lexicon Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
11.16
-0.18 (-1.59%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close11.34
Open11.37
Bid10.96 x 1000
Ask12.98 x 300
Day's Range11.12 - 11.37
52 Week Range10.96 - 18.00
Volume876,705
Avg. Volume695,720
Market Cap1.18B
Beta-0.08
PE Ratio (TTM)-8.42
EPS (TTM)-1.33
Earnings DateOct 30, 2017 - Nov 3, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.40
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.
    Markit5 days ago

    See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.

    Lexicon Pharmaceuticals Inc NASDAQ/NGS:LXRX

  • Capital Cube6 days ago

    ETFs with exposure to Lexicon Pharmaceuticals, Inc. : October 16, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Lexicon Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to LXRX-US. Comparing the performance and risk of Lexicon Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • News Flash: The FDA Just Approved a Breakthrough Diabetes Device
    Motley Fool14 days ago

    News Flash: The FDA Just Approved a Breakthrough Diabetes Device

    This first-in-class glucose monitoring system means a lot less pain for diabetics.

  • Capital Cube17 days ago

    ETFs with exposure to Lexicon Pharmaceuticals, Inc. : October 5, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Lexicon Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to LXRX-US. Comparing the performance and risk of Lexicon Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Lexicon Pharmaceuticals, Inc. :LXRX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017
    Capital Cube18 days ago

    Lexicon Pharmaceuticals, Inc. :LXRX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017

    Categories: Yahoo FinanceGet free summary analysis Lexicon Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 12.05 million, Net Earnings of USD -35.06 million. Change in operating cash flow of 32.69% compared to same period last year is about the same as change in earnings, likely no significant ... Read more (Read more...)

  • See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.
    Markit18 days ago

    See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.

    Lexicon Pharmaceuticals Inc NASDAQ/NGS:LXRX

  • PR Newswire25 days ago

    Lexicon Pharmaceuticals Initiates Patient Dosing In A Phase 1 Study Of LX9211

    THE WOODLANDS, Texas, Sept. 27, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (LXRX) today announced the company has initiated dosing in a Phase 1 study of LX9211, an orally-administered small molecule for the treatment of neuropathic pain. LX9211 is a selective inhibitor of AAK1 (adapter-associated kinase), which in preclinical studies demonstrated significant reduction in pain response in a series of pain models and was well-tolerated at and above efficacious doses in animals. "The successful filing of the IND followed by initiation of the first-in-human clinical study for LX9211 are significant milestones for the company as these events validate our robust preclinical results and bring us closer to demonstrating clinical proof-of-concept for LX9211 in patients with neuropathic pain," said Praveen Tyle, Ph.D., Lexicon's executive vice president, research and development.

  • PR Newswirelast month

    European Commission Approves XERMELO® (Telotristat Ethyl) For The Treatment Of Carcinoid Syndrome Diarrhea In Combination With Somatostatin Analog Therapy

    THE WOODLANDS, Texas, Sept. 19, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (LXRX), announced today that the European Commission has approved XERMELO® (telotristat ethyl) 250 mg as a first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. This approval allows for the marketing of XERMELO by Lexicon's collaborator, Ipsen, in the above indication in all 28 member states of the European Union, Norway and Iceland.

  • PR Newswirelast month

    Lexicon Pharmaceuticals To Present At The 2017 Cantor Fitzgerald Global Healthcare Conference

    Lonnel Coats, President and Chief Executive Officer, will present at the 2017 Cantor Fitzgerald Global Healthcare Conference on Monday, September 25, 2017 at 4:10 p.m. EDT (3:10 p.m. CDT) in New York City. A live audio webcast will be available in the "Investors" section of the Lexicon website at www.lexpharma.com/. Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions.

  • Morningstarlast month

    Slashing Fair Value Estimate on Lexicon Pharmaceuticals

    Sotagliflozin's side effects and competitor data lead to a near $10 cut.

  • Why Lexicon Pharmaceuticals Is Down 11% Today
    Motley Foollast month

    Why Lexicon Pharmaceuticals Is Down 11% Today

    Phase 3 data for its type 1 diabetes drug were published in a medical journal, and questions about safety risks could be crimping enthusiasm.

  • PR Newswirelast month

    New England Journal Of Medicine Publishes Data From Phase 3 inTandem3 Study Of Sotagliflozin In Patients With Type 1 Diabetes

    THE WOODLANDS, Texas, Sept. 13, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (LXRX) today announced that the New England Journal of Medicine (NEJM) published the results of the Phase 3 inTandem3 study of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, for the treatment of patients with type 1 diabetes on any background insulin therapy. The study met its primary endpoint with statistical significance, demonstrating the superiority of sotagliflozin 400 mg compared to placebo in the proportion of patients with A1C

  • See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • PR Newswirelast month

    Lexicon Pharmaceuticals Reports Positive Pooled Continuous Glucose Monitoring Data From Pivotal Phase 3 inTandem1 And inTandem2 Studies Of Sotagliflozin

    THE WOODLANDS, Texas, Sept. 8, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (LXRX) today announced positive pooled continuous glucose monitoring (CGM) data from the pivotal Phase 3 inTandem1 and inTandem2 studies of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor. At Week 24, patients treated with 200 mg and 400 mg doses of sotagliflozin spent a 5.4% and 11.7% greater proportion of the day, respectively, in the target glucose range of 70-180 mg/dL than those taking placebo, which translated into an additional 1.3 hours and 2.8 hours in a 24-hour period, respectively. "We are very pleased with today's results, which have important implications for the clinical management of glycemic control in patients with type 1 diabetes," said Paul Strumph, M.D., Lexicon's vice president of clinical research and development who leads the development program for sotagliflozin and has been living with type 1 diabetes for more than 50 years.

  • PR Newswirelast month

    Lexicon Pharmaceuticals Announces Four Data Presentations At The European Society Of Medical Oncology 2017 Congress

    THE WOODLANDS, Texas , Sept. 7, 2017 /PRNewswire/ --  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from four posters highlighting XERMELO ® (telotristat ethyl) will be presented ...

  • PR Newswirelast month

    Lexicon Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2017 Global Healthcare Conference

    Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer, will present at the Bank of America Merrill Lynch 2017 Global Healthcare Conference on Thursday, September 14, 2017 at 1:00 p.m. BST (7:00 a.m. CDT) in London. A live audio webcast will be available in the "Investors" section of the Lexicon website at www.lexpharma.com/. Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions.

  • PR Newswire2 months ago

    Lexicon Pharmaceuticals to Present New Clinical Data at the European Association for the Study of Diabetes 53rd Annual Meeting

    THE WOODLANDS, Texas, Sept. 5, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (LXRX) announced today that new clinical data for sotagliflozin will be presented at the upcoming European Association for the Study of Diabetes (EASD) 53rd annual meeting (September 11-15, Lisbon, Portugal). The four accepted abstracts, including two oral presentations, reflect Lexicon's efforts to improve current approaches to the clinical management of type 1 diabetes. Lexicon will share new efficacy and safety data for its investigational drug, sotagliflozin, including two oral presentations on pivotal data from the Phase 3 inTandem2 study and additional data from the JDRF study and two posters from the Phase 3 inTandem1 and Phase 2 dose-ranging studies.

  • 5 of the Most Hated Biotech Stocks on the Market: Are They Buys?
    Motley Fool2 months ago

    5 of the Most Hated Biotech Stocks on the Market: Are They Buys?

    Short-sellers have piled on Agios, Insys, Intercept, Lexicon, and Myriad Genetics. But are they wrong?

  • See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.

  • PR Newswire2 months ago

    Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal Phase 3 inTandem2 Study Of Sotagliflozin

    It was previously announced that both doses of sotagliflozin achieved the primary endpoint of the inTandem2 study, showing statistically significant reductions in A1C at 24 weeks in adult patients with type 1 diabetes on a background of optimized insulin. The new data showed that the A1C benefit was sustained over 52 weeks as well as achievement of all secondary endpoints for both sotagliflozin doses.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of LXRX earnings conference call or presentation 1-Aug-17 12:00pm GMT

    Q2 2017 Lexicon Pharmaceuticals Inc Earnings Call

  • PR Newswire3 months ago

    Lexicon Pharmaceuticals To Present At 2017 Wedbush PacGrow Healthcare Conference

    Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer, will present at the 2017 Wedbush PacGrow Healthcare Conference on Tuesday, August 15, 2017 at 10:20 a.m. EDT (9:20 a.m. CDT) in New York, NY. A live audio webcast will be available in the "Investors" section of the Lexicon website at www.lexpharma.com/. Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions.

  • Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LXRX-US : August 2, 2017
    Capital Cube3 months ago

    Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LXRX-US : August 2, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Lexicon Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • Associated Press3 months ago

    Lexicon reports 2Q loss

    On a per-share basis, the The Woodlands, Texas-based company said it had a loss of 33 cents. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • Lexicon Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LXRX) : August 1, 2017
    Capital Cube3 months ago

    Lexicon Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LXRX) : August 1, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Lexicon Pharmaceuticals, Inc. a score of 18. Our analysis is based on comparing Lexicon Pharmaceuticals, Inc. with the following peers – BioTime, Inc., Regeneron Pharmaceuticals, Inc., Ultragenyx Pharmaceutical, Inc., Illumina, Inc., Aerie Pharmaceuticals, Inc., Esperion Therapeutics, Inc., Ligand Pharmaceuticals Incorporated, Thermo Fisher Scientific Inc., BioMarin Pharmaceutical Inc. ... Read more (Read more...)